Zhen-Hai Lu (Zhenhai Lu)

ORCID

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 8

Top Venues

Targeted oncology

PLoS medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Yuan Li, Weili Zhang, Jie Du, Jinlong Hu, Ruixi Hu, Ziyang Zeng, E-Er-Man-Bie-Ke Jin-Si-Han, Shaopu Lian, Hao Wang, Yunfeng Li, Zhizhong Pan, Cheng Feng, Xuan Zhang, Zhen-Hai Lu
Efficacy and Safety of Neoadjuvant Subcutaneous Envafolimab in dMMR/MSI-H Locally Advanced Colon Cancer. Targeted oncology 19 (4) (2024)
Yuan Li, Weili Zhang, Jie Du, Jinlong Hu, Ruixi Hu, Ziyang Zeng, E-Er-Man-Bie-Ke Jin-Si-Han, Shaopu Lian, Hao Wang, Yunfeng Li, Zhizhong Pan, Cheng Feng, Xuan Zhang, Zhen-Hai Lu
Efficacy and Safety of Neoadjuvant Subcutaneous Envafolimab in dMMR/MSI-H Locally Advanced Colon Cancer. Targeted oncology (2024)
De-Sheng Wang, Chao Ren, Shan-Shan Li, William Pat Fong, Xiao-Jun Wu, Jian Xiao, Bin-Kui Li, Yun Zheng, Pei-Rong Ding, Gong Chen, Miao-Zhen Qiu, Zhi-Qiang Wang, Feng-Hua Wang, Hui-Yan Luo, Feng Wang, Xiao-Zhong Wang, Ling-Yun Wang, De-Jin Xie, Tao Chen, Li-Ren Li, Zhen-Hai Lu, Xiao-Hui Zhai, Tian-Shu Liu, Ying Yuan, Jia-Qi Chen, Qiong Tan, Zhi-Zhong Pan, De-Sen Wan, Rong Zhang, Yun-Fei Yuan, Rui-Hua Xu, Yu-Hong Li
Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial. PLoS medicine 21 (5) (2024)
De-Sheng Wang, Chao Ren, Shan-Shan Li, William Pat Fong, Xiao-Jun Wu, Jian Xiao, Bin-Kui Li, Yun Zheng, Pei-Rong Ding, Gong Chen, Miao-Zhen Qiu, Zhi-Qiang Wang, Feng-Hua Wang, Hui-Yan Luo, Feng Wang, Xiao-Zhong Wang, Ling-Yun Wang, De-Jin Xie, Tao Chen, Li-Ren Li, Zhen-Hai Lu, Xiao-Hui Zhai, Tian-Shu Liu, Ying Yuan, Jia-Qi Chen, Qiong Tan, Zhi-Zhong Pan, De-Sen Wan, Rong Zhang, Yun-Fei Yuan, Rui-Hua Xu, Yu-Hong Li
Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial. PLoS medicine 21 (5) (2024)
Yuan Li, Weili Zhang, Jie Du, Jinlong Hu, Ruixi Hu, Ziyang Zeng, E-Er-Man-Bie-Ke Jin-Si-Han, Shaopu Lian, Hao Wang, Yunfeng Li, Zhizhong Pan, Cheng Feng, Xuan Zhang, Zhen-Hai Lu
Efficacy and Safety of Neoadjuvant Subcutaneous Envafolimab in dMMR/MSI-H Locally Advanced Colon Cancer. Targeted oncology 19 (4) (2024)
De-Sheng Wang, Chao Ren, Shan-Shan Li, William Pat Fong, Xiao-Jun Wu, Jian Xiao, Bin-Kui Li, Yun Zheng, Pei-Rong Ding, Gong Chen, Miao-Zhen Qiu, Zhi-Qiang Wang, Feng-Hua Wang, Hui-Yan Luo, Feng Wang, Xiao-Zhong Wang, Ling-Yun Wang, De-Jin Xie, Tao Chen, Li-Ren Li, Zhen-Hai Lu, Xiao-Hui Zhai, Tian-Shu Liu, Ying Yuan, Jia-Qi Chen, Qiong Tan, Zhi-Zhong Pan, De-Sen Wan, Rong Zhang, Yun-Fei Yuan, Rui-Hua Xu, Yu-Hong Li
Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial. PLoS medicine 21 (5) (2024)
Yuan Li, Weili Zhang, Jie Du, Jinlong Hu, Ruixi Hu, Ziyang Zeng, E-Er-Man-Bie-Ke Jin-Si-Han, Shaopu Lian, Hao Wang, Yunfeng Li, Zhizhong Pan, Cheng Feng, Xuan Zhang, Zhen-Hai Lu
Correction to: Efficacy and Safety of Neoadjuvant Subcutaneous Envafolimab in dMMR/MSI-H Locally Advanced Colon Cancer. Targeted oncology (2024)
Yuan Li, Weili Zhang, Jie Du, Jinlong Hu, Ruixi Hu, Ziyang Zeng, E-Er-Man-Bie-Ke Jin-Si-Han, Shaopu Lian, Hao Wang, Yunfeng Li, Zhizhong Pan, Cheng Feng, Xuan Zhang, Zhen-Hai Lu
Efficacy and Safety of Neoadjuvant Subcutaneous Envafolimab in dMMR/MSI-H Locally Advanced Colon Cancer. Targeted oncology (2024)

Zhen-Hai Lu.css-eqlu8i{font-size:small;padding-left:4px;} (Zhenhai Lu)

Publication Activity (10 Years)

Top Topics

Top Venues

Zhen-Hai Lu (Zhenhai Lu)